Krish Ramadurai
Krish is a Partner at AIX Ventures, where he leads technical due diligence, investment sourcing, and portfolio operations across the firm's AI, healthcare, and life sciences practices. He has led and managed over 40 early- and growth-stage investments across multiple top-decile performing funds, driving a cumulative portfolio enterprise value exceeding $20 billion. His investment track record includes notable exits such as Volumetric Biotechnologies (acquired by 3D Systems), PathologyWatch (acquired by Sonic Healthcare), Trials.AI (acquired by ZS Associates), and Insilico Medicine (IPO announced). Krish has backed several unicorn companies and supported over 20 major scientific breakthroughs, including the world's first AI-designed drug to reach human trials and the first therapeutic discovered using a 3D-bioprinted tissue disease model.
Krish is a Harvard- and Oxford-trained research scientist and biomolecular engineer, multi-published author, advisor, lecturer, and a former researcher at Harvard and MIT. While at Harvard’s Belfer Center for Science and International Affairs & Taubman Center for State and Local Government, he worked alongside former U.S. Secretary of Defense Ash Carter and Nobel Laureate Economist Michael Kremer on the USAID Development Innovation Ventures Fund. During this time, he published three internationally released books on applied engineering and medicine, featured in Barnes & Noble, the National Institute of Health (NIH), and the library collections of Oxford, MIT, Harvard, Yale, and Princeton.
Krish has been a board member for numerous leading AI-enabled health and techbio companies and is a venture advisor for Nucleate and the National Venture Capital Association (NVCA) Venture Forward Program. He is also a member of Oxford University’s Institute of Biomedical Engineering (IBME), the American Society of Biomechanics (ASB), the American Institute of Chemical Engineers (AIChE), and the Advanced Research Projects Agency for Health (ARPA-H). His thought leadership has been featured in leading media outlets, including the Wall Street Journal, Venture Capital Journal, Yahoo Finance, TechCrunch, Business Insider, the World Economic Forum, and Nikkei Asia.
AIX Ventures
Next-Gen Medicine: AI-Powered Advances Reshaping Human Therapeutics
-
Dive into the cutting-edge today, not just the promises of tomorrow. This dynamic breakout session features biotech visionaries actively leveraging machine learning and AI to transform the engineering of human therapeutics. Hear firsthand from industry pioneers pushing the boundaries—from accelerating drug target discovery to streamlining clinical development pipelines. Learn how advanced analytics and big data are already enhancing personalized medicine, boosting clinical success rates, and rapidly reshaping the future landscape of healthcare. Don't miss this inside look at the real-world innovations redefining what's possible in therapeutic discovery and precision medicine.
Disrupt, Discover, Deliver: The New Wave of Tech Bio Investments
-
Explore how emerging tech bio ventures are reshaping traditional market dynamics and capturing the attention of forward-thinking investors. This session dives into key trends in synthetic biology, computational life sciences, and platform-based drug discovery, highlighting strategies to accelerate breakthroughs and unlock value at scale. Hear seasoned venture experts discuss the evolving regulatory and investment landscapes, share approaches to building high-growth portfolios, and provide insights on nurturing disruptive companies from seed to maturity. Join a candid dialogue on how collaboration, cutting-edge research, and risk management converge to drive the future of tech bio innovation.
Conference Pass
2,495
USD
Keynotes & Firesides
Workshops & Breakouts
1:1 Partnering App
Meals & Receptions
Session Recordings
Until Friday April 18th
Full Rate:
$3,495
